Search
muvalaplin
Indications:
- elevations of lipoprotein(a) [Lp(a)] > 50 mg/dL
Dosage:
- 100-800 mg daily
Adverse effects:
- not associated with tolerability concerns
Mechanism of action:
- selective small molecule inhibitor of Lp(a) formation
- lowers Lp(a) levels as much as 65% after daily administration for 14 days
General
metabolic agent (metabolic modifier)
amine
carboxylate
aromatic compound
References
- Nicholls SJ, Nissen SE, Fleming C et al
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation.
A Randomized Clinical Trial.
JAMA. Published online August 28, 2023.
PMID: 37638695
https://jamanetwork.com/journals/jama/fullarticle/2808864
- Owens B
New Pill Successfully Lowers Lp(a) Levels
Medscape. Nov 19, 2024
https://www.medscape.com/viewarticle/new-pill-successfully-lowers-lp-levels-2024a1000l13